We studied the immunogenicity of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin (PT-9K/129G), filamentous haemagglutinin, and a 69-kilodalton protein, pertactin, in 30 children aged 12 to 24 months and in 80 infants aged 2 to 4 months. A significant increase of the neutralizing titer and of the titers against pertussis toxin, filamentous hemagglutinin, and pertactin, as determined by enzyme-linked immunosorbent assay, was achieved after three doses of vaccine in all the children; a significant increase of these antibody titers was obtained in 100%, 96.1%, 93.5%, and 98.7% of the infants, respectively.
Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with FHA and pertactin in infants and children / Podda, A.; CARAPELLA DE LUCA, E.; Titone, L.; Casadei, A. M.; Cascio, A.; Bartalini, M.; Volpini, G.; Peppoloni, Samuele; Marsili, I.; Nencioni, L. AND RAPPUOLI R.. - In: THE JOURNAL OF PEDIATRICS. - ISSN 0022-3476. - STAMPA. - 123 (19):(1993), pp. 81-84.
Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with FHA and pertactin in infants and children
PEPPOLONI, Samuele;
1993
Abstract
We studied the immunogenicity of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin (PT-9K/129G), filamentous haemagglutinin, and a 69-kilodalton protein, pertactin, in 30 children aged 12 to 24 months and in 80 infants aged 2 to 4 months. A significant increase of the neutralizing titer and of the titers against pertussis toxin, filamentous hemagglutinin, and pertactin, as determined by enzyme-linked immunosorbent assay, was achieved after three doses of vaccine in all the children; a significant increase of these antibody titers was obtained in 100%, 96.1%, 93.5%, and 98.7% of the infants, respectively.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
